Masimo Addresses the Inaccurate and Misleading Claims that
Covidien Continues to Make Regarding Nellcor Pulse Oximetry Performance
IRVINE, Calif.--(BUSINESS WIRE)--Jul. 13, 2015--
Masimo (NASDAQ: MASI), the inventor of measure-through motion and low
perfusion pulse oximetry, today renewed its $1,000,000 (USD) performance
guarantee that Masimo SET® Pulse Oximetry will outperform all
Nellcor (part of Covidien and now Medtronic) pulse oximeters. Under the
guarantee, if Masimo SET is proven not to
be superior to all Nellcor pulse oximeters, including the three that
Covidien announced have received FDA 510(k) clearance with motion
claims, Masimo will pay up to $1,000,000 to help a hospital acquire that
"As a medical technology company, we believe it is our obligation to be
truthful and open in our advertising because ultimately patient care is
at issue. We continue to be perplexed by the misleading marketing
tactics of our competitor," stated Joe Kiani, Founder and CEO of Masimo.
“We are concerned that customers may be misled and we hope our guarantee
will cause them to question what they are being told and evaluate the
performance of the technologies for themselves.”
In addition to renewing the $1 million guarantee, Masimo has updated its
website to respond to each of the inaccurate and misleading claims in
Masimo makes four promises to every hospital that to date, Covidien has
not been willing to make:
We will demonstrate the superior pulse oximetry performance of Masimo
SET® over Nellcor in a side-by-side comparison.
We will provide independent and objective scientific evidence of
Masimo SET® superiority over Nellcor, as well as the
evidence demonstrating Masimo SET® helps clinicians improve
clinical and financial outcomes.
We strongly encourage scientific side-by-side evaluations of Masimo SET®
and Nellcor pulse oximetry in challenging conditions with automated
We are so confident that an objective comparison will reveal the
clinical superiority of Masimo SET®, we continue to offer a
$1,000,000 performance guarantee.
Please note: This offer is available only to hospitals whose goal is to
upgrade their pulse oximetry hospital-wide to the new standard.
Important details, conditions, and qualifications for the challenge are
available at http://www.masimo.com/1millionrules.htm.
Masimo (NASDAQ: MASI) is the global leader in
innovative noninvasive monitoring technologies that significantly
improve patient care—helping solve “unsolvable” problems. In 1995, the
company debuted Measure-Through Motion and Low Perfusion pulse oximetry,
known as Masimo SET®, which virtually eliminated false alarms and
increased pulse oximetry’s ability to help clinicians detect
life-threatening events. In 2005, Masimo introduced rainbow ® Pulse
CO-Oximetry™ technology, allowing noninvasive and continuous monitoring
of blood constituents that previously required invasive procedures;
total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®), PVI®, and perfusion index (PI), in
addition to measure-through motion SpO2, and pulse rate. In 2008, Masimo
introduced Patient SafetyNet™, a remote monitoring and wireless
clinician notification system designed to help hospitals avoid
preventable deaths and injuries associated with failure to rescue
events. In 2009, Masimo introduced rainbow® Acoustic Monitoring™, the
first-ever commercially available noninvasive and continuous monitoring
of acoustic respiration rate (RRa™). Founded in 1989, Masimo has the
mission of “Improving Patient Outcome and Reducing Cost of Care … by
Taking Noninvasive Monitoring to New Sites and Applications®.”
Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes
forward-looking statements as defined in Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in
connection with the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a
result of various risk factors related to MightySat, including our
belief in the breakthrough ability of Masimo SET® pulse oximetry to
measure-through motion and low perfusion; as well as other factors
discussed in the “Risk Factors” section of our most recent reports filed
with the Securities and Exchange Commission (“SEC”), which may be
obtained for free at the SEC’s website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today’s date. We do not undertake any obligation to update, amend or
clarify these statements or the “Risk Factors” contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome
and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks
or registered trademarks of Masimo Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150713005539/en/
Irene Paigah, 858-859-7001